- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04317079
Effects of Hydroxytyrosol Administration in Anthropometric Parameters in Overweight and Obese Women
Evaluation of the Effects of the Administration of 5 Milligrams and 15 Milligrams of Hydroxytyrosol, an Extra Virgin Olive Oil Phenolic Compound, Versus Placebo, Combined With Diet, in Anthropometric Parameters in Overweight and Obese Women
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hydroxytyrosol is an extra virgin olive oil phenolic compound which has known protective effects in LDL oxidation and reduces oxidative stress. Olive oil has been associated with enhanced weight loss, and hydroxytyrosol could have a potential role in this.
Participants entered the study after signing the informed consent document. Detailed medical and family history was taken at baseline visit, and measurement of height, body weight, body fat and visceral fat were also made. Each participant visited a dietitian the same day and written consultation concerning the diet to be followed was given, based on Mediterranean diet and 500 kilocalories below their estimated Basal Metabolic Rate. The above measurements and dietitian consultation were repeated in each visit during the intervention (4,12 and 24 weeks).
Baseline laboratory testing was made including urea, creatinine, aminotransferases and fasting lipids and glucose, while serum and plasma were stored in -80 Celsius degrees for future analyses. Blood samples were also taken at 4, 12 and 24 weeks of the intervention.
All participants had an identical meal test at baseline, at 12 and 24 months and blood samples were collected at times 0, 30, 60, 90, 120, 150 and 180 minutes after meal consumption. Samples were also stored in -80 Celsius degrees for future analyses.
Each participant received in each visit prepackaged the quantity of capsules until the next scheduled visit, and the used empty blisters were returned in the following visit in order to assess compliance in capsules consumption. 24-hour diet recalls were used to assess compliance to diet.
In each visit an investigation concerning potential adverse events was made and data were recorded.
A communication was obtained with each participant who discontinued the study before 24 weeks, the reasons for discontinuation were recorded and data obtained until their last visit before study discontinuation were used in analyses.
Paired analyses were made using the system Statistical Package for the Social Sciences comparing all study groups before and after the intervention.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Athens, Greece, 11527
- Diabetes Clinical Research Laboratory, 1st Department of Propaedeutic Internal Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Overweight and obese women. Stable body weight (<5% variation) during the past 3 months before enrollment. Stable hypolipidemic treatment for at least 3 months before enrollment.
Exclusion Criteria:
- Diabetes mellitus
- Neoplasms
- Autoimmune conditions
- Psychiatric disorders (excluding stable depressive disorder)
- Hyper/hypo-thyroidism with recent changes in medical treatment during the past 6 months before enrollment
- Renal impairment, defined as estimated Glomerular Filtration Rate (MDRD) <60millilitres/min
- Heart failure, defined as left ventricle Ejection Fraction <40%, use of diuretics or other treatment due to heart failure (antihypertensive medications allowed)
- Impaired liver function, defined as liver transaminases values twice above the upper normal range
- Malabsorption status (inflammatory bowel disease, previous bariatric surgery, chronic pancreatitis)
- Medical treatment known to influence body weight (steroids, oestrogens/ progesterone, topiramate, mirtazapine or anti-obesity treatment)
- Unwillingness to participate to the study
- Baseline waist circumference >130cm due to technical difficulties in visceral fat measurement
- Pregnancy, lactation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 15mg of hydroxytyrosol
15 milligrams of hydroxytyrosol given as 2 capsules containing 2.5mg of hydroxytyrosol each given three times daily before main meals (totally 6 capsules daily) in combination with diet
|
Administration of hydroxytyrosol in doses 15mg and 5 mg compared to placebo for 6 months
Consultation by a dietitian was offered to all participants
|
Active Comparator: 5mg of hydroxytyrosol
5 milligrams of hydroxytyrosol given as 2 capsules containing 2.5mg of hydroxytyrosol each given in the morning and at night before meals and 2 capsules of placebo before lunch (totally 6 capsules daily) in combination with diet
|
Administration of hydroxytyrosol in doses 15mg and 5 mg compared to placebo for 6 months
Consultation by a dietitian was offered to all participants
|
Placebo Comparator: placebo
2 capsules of placebo given 3 times daily before meals (totally 6 capsules daily) in combination with diet
|
Consultation by a dietitian was offered to all participants
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in body weight
Time Frame: Baseline, 4,12 and 24 weeks
|
Measurement of body weight via TANITA Bioelectrical Impedance Analysis technology
|
Baseline, 4,12 and 24 weeks
|
Change in body fat mass
Time Frame: Baseline, 4,12 and 24 weeks
|
Measurement of body fat mass via bioelectrical impedance (TANITA Bioelectrical Impedance Analysis technology)
|
Baseline, 4,12 and 24 weeks
|
Change in visceral fat
Time Frame: Baseline, 4, 12 and 24 weeks
|
Measurement via TANITA technology
|
Baseline, 4, 12 and 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in blood lipids
Time Frame: Baseline, 12 and 24 weeks
|
Measurement of serum total cholesterol, high-density lipoprotein and triglycerides
|
Baseline, 12 and 24 weeks
|
Changes in blood glucose
Time Frame: Baseline, 12 and 24 weeks
|
Measurement of serum glucose
|
Baseline, 12 and 24 weeks
|
Changes in blood insulin
Time Frame: Baseline, 12 and 24 weeks
|
Measurement of serum insulin
|
Baseline, 12 and 24 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Nikolaos Tentolouris, MD,PhD, National Kapodistrian University of Athens
Publications and helpful links
General Publications
- Cotrim BA, Joglar J, Rojas MJ, del Olmo JM, Macias-Gonzalez M, Cuevas MR, Fito M, Munoz-Aguayo D, Planells MI, Farre M, de Fonseca FR, de la Torre R. Unsaturated fatty alcohol derivatives of olive oil phenolic compounds with potential low-density lipoprotein (LDL) antioxidant and antiobesity properties. J Agric Food Chem. 2012 Feb 1;60(4):1067-74. doi: 10.1021/jf203814r. Epub 2012 Jan 20.
- Peyrol J, Riva C, Amiot MJ. Hydroxytyrosol in the Prevention of the Metabolic Syndrome and Related Disorders. Nutrients. 2017 Mar 20;9(3):306. doi: 10.3390/nu9030306.
- Colica C, Di Renzo L, Trombetta D, Smeriglio A, Bernardini S, Cioccoloni G, Costa de Miranda R, Gualtieri P, Sinibaldi Salimei P, De Lorenzo A. Antioxidant Effects of a Hydroxytyrosol-Based Pharmaceutical Formulation on Body Composition, Metabolic State, and Gene Expression: A Randomized Double-Blinded, Placebo-Controlled Crossover Trial. Oxid Med Cell Longev. 2017;2017:2473495. doi: 10.1155/2017/2473495. Epub 2017 Aug 9.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HydroxytyrosolStudy
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Body Weight
-
University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI)RecruitingWeight Loss | Weight, BodyUnited States
-
Oslo University HospitalMayo Clinic; Sorlandet Hospital HF; The Hospital of Vestfold; University of TwenteActive, not recruiting
-
Fred Hutchinson Cancer CenterCompletedWeight Loss | Weight, BodyUnited States
-
Pusan National University HospitalCompletedWeight Change, Body
-
Xinhua Hospital, Shanghai Jiao Tong University...Not yet recruiting
-
Erik Ramirez LopezCompletedWeight Loss | Body CompositionMexico
-
University of LeedsDietary Assessment LtdRecruitingWeight Loss | Colorectal Surgery | Weight Change, Body | Gastroenterology SurgeryUnited Kingdom
-
University of TennesseeMayo Clinic; National Institute of Diabetes and Digestive and Kidney Diseases...CompletedSmoking Cessation | Weight Change, BodyUnited States
-
Virta HealthActive, not recruiting
-
University of Colorado, DenverNational Heart, Lung, and Blood Institute (NHLBI)Enrolling by invitationObesity | Weight Change, BodyUnited States
Clinical Trials on Hydroxytyrosol
-
Instituto de Investigación Hospital Universitario...Completed
-
Hong Kong Children's HospitalThe University of Hong KongRecruiting
-
Bambino Gesù Hospital and Research InstituteCompleted
-
IMDEA FoodCompleted
-
The Methodist Hospital Research InstituteCompleted
-
University of IoanninaCompletedInflammation | Body Weight | Oxidative Stress | Homocystine; Metabolic DisorderGreece
-
University of AthensRecruitingCoronary Artery DiseaseGreece
-
Harokopio UniversityNational and Kapodistrian University of AthensCompleted
-
Universidad Católica San Antonio de MurciaCompleted
-
University Rovira i VirgiliRecruiting